Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2003

View Archived Issues

Positive outcome for phase II study of Periostat as adjunctive treatment for rosacea

Preparations for Italian phase II Remune study

Antitumor effects described for FOLFOX4 + erlotinib in colorectal cancer

New therapies for fibromyalgia discussed at EULAR 2003

Requip OCR enters phase III testing

Approvable letter issued for Wellbutrin XL

Olux cleared for marketing in U.K.

FDA advisory committee issues positive decision on Photofrin PDT efficacy in Barrett's esophagus

MedImmune reviews pipeline progress

LAS-34475 reported safe and effective in the treatment of osteoarthritis

Antitumor effects described for homoharringtonine in acute and chronic leukemia

New inhibitors of ileal bile acid transport under study at Sankyo

Merck researchers identify alpha5-selective GABA-A receptor modulators for AD therapy

HER2 inhibitors prepared and tested by Takeda scientists

Novel series of p38 MAP kinase inhibitors in Ono pipeline

Morinaga Milk claims ACE-inhibitory tripeptide with in vivo antihypertensive activity

Novel potentiators of glucose transport designed by Ajinomoto researchers

Positive opinion for Onsenal in familial adenomatous polyposis in Europe

European CPMP recommends approval of Stalevo

Nycomed obtains license to commercialize MT-100 in Nordic countries

Multiple-dose phase I study of ETC-642 commences in stable atherosclerosis patients

Amgen exercises option to HuMax-IL-15

ABT-202, first compound to enter the clinic from NeuroSearch/Abbott collaboration

New phase I/II trial of Dacogen plus carboplatin for advanced solid tumors

Pivanex studied in combination with docetaxel for NSCLC

Indications for Forcaltonin expanded in Europe

Low-dose Prempro launched

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...